Evaluation Of Salivary PGE2 In Chronic Periodontitis Before And After Phase I Therapy A Clinical-Biochemical Study

Abstract

To evaluate the levels of prostaglandin E2 (PGE2) in chronic periodontitis and assess the relationship between the PGE2 and chronic periodontitis before and after phase I therapy. The study consisted of 15 patients with generalized chronic periodontitis. They were
assessed based on the clinical parameters; Gingival index (GI), Plaque index (PI), Bleeding on probing (BOP), pocket depth (PD), Clinical attachment level (CAL) along with the evaluation of salivary PGE2 levels at baseline and completion of Phase I therapy. They were further assessed after 6 weeks for the clinical parameters and PGE2 levels were determined by enzyme-linked immunosorbent assay (ELISA). The clinical parameters (GI,PI,BOP,PD,CAL) showed a significant (p<0.0001) decrease after phase I therapy assessed after 6 weeks. PGE2 levels were also decreased significantly with a greater mean difference (207.1) after phase I therapy. There was also a positive correlation between the changes in the PGE2 levels after Phase I therapy and the clinical parameters recorded. The study suggests that PGE2 can be used as a diagnostic biomarker and a potential chair-side diagnostic kit along with the use of saliva for
sample collection as a reliable and non-invasive approach for the detection of biomarkers.